Overview

SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

Status:
Active, not recruiting

Trial end date:
2022-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to demonstrate that SYD985 [(vic-)trastuzumab duocarmazine] is superior to physician's choice in prolonging progression free survival.

Phase:

Phase 3

Details

Lead Sponsor:

Byondis B.V.
Synthon Biopharmaceuticals BV

Treatments:

Capecitabine
Lapatinib
Trastuzumab
Vinorelbine